157 related articles for article (PubMed ID: 37899398)
1. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract][Full Text] [Related]
2. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
3. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
4. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
5. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
Chino H; Sekine A; Kitamura H; Kato T; Ogura T
Lung Cancer; 2015 Dec; 90(3):610-3. PubMed ID: 26452431
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
Kaira K; Naruse I; Shimizu K; Asao T
J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
[TBL] [Abstract][Full Text] [Related]
9. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
[TBL] [Abstract][Full Text] [Related]
11. First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews.
Wu R; Liu S; Lv G; Deng C; Wang R; Zhang S; Zhu D; Wang L; Lei Y; Luo Z
Anticancer Drugs; 2023 Feb; 34(2):294-301. PubMed ID: 36730620
[TBL] [Abstract][Full Text] [Related]
12. Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
Nukaga S; Naoki K; Kamo T; Masuzawa K; Yasuda H; Soejima K; Betsuyaku T
Mol Clin Oncol; 2016 Jun; 4(6):1085-1087. PubMed ID: 27284449
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
Zhao M; Liu S; Xie R; Zhang J; Li J
Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
[TBL] [Abstract][Full Text] [Related]
14. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
15. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
[TBL] [Abstract][Full Text] [Related]
16. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
[TBL] [Abstract][Full Text] [Related]
17. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
Nitawaki T; Sakata Y; Kawamura K; Ichikado K
BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
[TBL] [Abstract][Full Text] [Related]
18. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Ikeda S; Yoshioka H; Arita M; Sakai T; Sone N; Nishiyama A; Niwa T; Hotta M; Tanaka T; Ishida T
Jpn J Clin Oncol; 2015 Feb; 45(2):221-4. PubMed ID: 25398579
[TBL] [Abstract][Full Text] [Related]
19. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
[No Abstract] [Full Text] [Related]
20. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
